NCT03860272 2026-03-30Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT06322108 2025-05-08Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)Immune Oncology Research InstitutePhase 2 Recruiting45 enrolled
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available